Lupin and Boehringer to co-market anti-diabetes drug in India

Domestic pharma company Lupin and MNC firm Boehringer Ingelheim announced a joint strategic alliance for co-marketing an anti-diabetic drug, linagliptin, a novel dipeptidylpeptidase-4 (DPP-4) inhibitor in India.

Source: Mumbai News

Related posts:

HSC students welcome 10-minute reading time before paper, say it helps them organize Creativity happens when mind and body are empty or full: Aditi Mangaldas Protests after racial abuse by traffic cop In erstwhile mill district Sewri, towers and tenements coexist, yet struggle to get along